Uncategorized

Patent Cliff or Patent Opportunity? Mapping Blockbuster Drug Expirations for Strategic Supply Chain Readiness

Patent cliffs aren’t just a legal event—they’re a supply-chain stress test.
If you work in pharma operations, procurement, or commercial planning, you’ve probably felt the same pattern: a blockbuster’s exclusivity window closes, competitors surge, pric…

Patent Cliff or Patent Opportunity? Mapping Blockbuster Drug Expirations for Strategic Supply Chain Readiness Read Post »

Uncategorized

How to Win the Biosimilar Patent Dance: A Litigation Strategy Guide for Biologics and Biosimilar Applicants

The biosimilar “patent dance” isn’t a formality—it’s the first move in a multi-year chess match.
If you’re a biologics innovator or a biosimilar applicant, the rules of engagement are familiar: exchange lists, negotiate scope, litigate, and—if you’re…

How to Win the Biosimilar Patent Dance: A Litigation Strategy Guide for Biologics and Biosimilar Applicants Read Post »

Uncategorized

The Paragraph IV Playbook: How Generic Manufacturers Win 180-Day Exclusivity and Beat Brand Pharma to Market

Generic winners don’t “wait” for exclusivity—they engineer it.
In the Paragraph IV world, 180-day exclusivity is often described like a prize at the end of a race. But the real story is that exclusivity is a strategy outcome—built through timing, lit…

The Paragraph IV Playbook: How Generic Manufacturers Win 180-Day Exclusivity and Beat Brand Pharma to Market Read Post »

Biotechblog
Scroll to Top